```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1635kxh

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 26  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 27  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 28  Oct 21  EVENTLINE has been reloaded
 NEWS 29  Oct 24  BEILSTEIN adds new search fields
 NEWS 30  Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
 NEWS 31  Oct 25  MEDLINE SDI run of October 8, 2002
 NEWS 32  Nov 18  DKILIT has been renamed APOLLIT
 NEWS 33  Nov 25  More calculated properties added to REGISTRY
 NEWS 34  Dec 02  TIBKAT will be removed from STN
 NEWS 35  Dec 04  CSA files on STN
 NEWS 36  Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
 NEWS 37  Dec 17  TOXCENTER enhanced with additional content
 NEWS 38  Dec 17  Adis Clinical Trials Insight now available on STN
 NEWS 39  Dec 30  ISMEC no longer available

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
```

```
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:34:45 ON 08 JAN 2003

=> b medline caplus lifesci embase uspatfull biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:35:00 ON 08 JAN 2003

FILE 'CAPLUS' ENTERED AT 16:35:00 ON 08 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 16:35:00 ON 08 JAN 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'EMBASE' ENTERED AT 16:35:00 ON 08 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'USPATFULL' ENTERED AT 16:35:00 ON 08 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:35:00 ON 08 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s tacii promoter
L1          30 TACII PROMOTER

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2          30 DUP REM L1 (0 DUPLICATES REMOVED)

=> d l2 ibib abs tot

L2   ANSWER 1 OF 30  USPATFULL
ACCESSION NUMBER:        2002:258818  USPATFULL
TITLE:                   Bacterial host strains
INVENTOR(S):             Chen, Christina Yu-Ching, Hillsborough, CA, UNITED
                         STATES
PATENT ASSIGNEE(S):      GENENTECH, INC. (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2002142388      A1   20021003
APPLICATION INFO.:       US 2001-11125      A1   20011207  (10)

                               NUMBER        DATE
                         ---------------- --------
```

PRIORITY INFORMATION: US 2000-256162P 20001214 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 2303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An E. coli strain is described that is deficient in chromosomal degP and prc encoding protease DegP and Prc, respectively, and harbors a mutant spr gene that encodes a protein that suppresses growth phenotypes exhibited by strains harboring prc mutants. Preferably, the strain comprises nucleic acid encoding a polypeptide heterologous to the strain, so that a heterologous polypeptide can be produced therefrom.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 30 USPATFULL
ACCESSION NUMBER: 2001:107645 USPATFULL
TITLE: Process for bacterial production of polypeptides
INVENTOR(S): Leung, Woon-Lam Susan, San Mateo, CA, United States
Swartz, James R., Menlo Park, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258560	B1	20010710
APPLICATION INFO.:	US 2000-607756		20000629 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-422712, filed on 21 Oct 1999, now patented, Pat. No. US 6180367

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106052P	19981028 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Guzo, David
ASSISTANT EXAMINER: Leffers, Jr., Gerald G.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1789
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Processes are described for recovering heterologous polypeptide from bacterial cells, including the periplasm and cytoplasm. One process involves culturing the bacterial cells, which cells comprise nucleic acid encoding phage lysozyme and nucleic acid encoding a protein that displays DNA-digesting activity, wherein these nucleic acids are linked to a first promoter, and nucleic acid encoding the heterologous polypeptide, which nucleic acid is linked to a second promoter, under certain conditions to produce a broth lysate; and recovering accumulated heterologous polypeptide from the broth lysate. Another process entails culturing bacterial cells that comprise nucleic acid encoding phage lysozyme, gene t, and nucleic acid encoding a protein that displays DNA-digesting activity under the control of a signal sequence for secretion of said DNA-digesting protein, wherein said nucleic acids are linked to one or more promoters, and nucleic acid encoding the heterologous polypeptide and a signal sequence for secretion of the heterologous polypeptide, which nucleic acid encoding the heterologous polypeptide is linked to a another promoter that is inducible, under

certain conditions to produce a broth lysate; and recovering accumulated heterologous polypeptide from the broth lysate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 30 USPATFULL

ACCESSION NUMBER:	2001:40006 USPATFULL
TITLE:	Platelet-activating factor acetylhydrolase
INVENTOR(S):	Cousens, Lawrence S., Oakland, CA, United States Eberhardt, Christine D., Auburn, WA, United States Gray, Patrick, Seattle, WA, United States Trong, Hai Le, Edmonds, WA, United States Tjoelker, Larry W., Kirkland, WA, United States Wilder, Cheryl L., Seattle, WA, United States
PATENT ASSIGNEE(S):	ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6203790	B1	20010320
APPLICATION INFO.:	US 2000-577758		20000523 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-10715, filed on 22 Jan 1998 Continuation of Ser. No. US 1995-480658, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-318905, filed on 6 Oct 1994, now patented, Pat. No. US 5641669 Continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Patterson, Jr., Charles L.
LEGAL REPRESENTATIVE:	Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS:	2
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT:	2570

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 30 USPATFULL

ACCESSION NUMBER:	2001:14225 USPATFULL
TITLE:	Process for bacterial production of polypeptides
INVENTOR(S):	Leung, Woon-Lam Susan, San Mateo, CA, United States Swartz, James R., Menlo Park, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6180367	B1	20010130
APPLICATION INFO.:	US 1999-422712		19991021 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106052P	19981028 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Guzo, David

ASSISTANT EXAMINER: Leffers, Jr., Gerald George
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Processes are described for recovering heterologous polypeptide from bacterial cells, including the periplasm and cytoplasm. One process involves culturing the bacterial cells, which cells comprise nucleic acid encoding phage lysozyme and nucleic acid encoding a protein that displays DNA-digesting activity, wherein these nucleic acids are linked to a first promoter, and nucleic acid encoding the heterologous polypeptide, which nucleic acid is linked to a second promoter, under certain conditions to produce a broth lysate; and recovering accumulated heterologous polypeptide from the broth lysate. Another process entails culturing bacterial cells that comprise nucleic acid encoding phage lysozyme, gene t, and nucleic acid encoding a protein that displays DNA-digesting activity under the control of a signal sequence for secretion of said DNA-digesting protein, wherein said nucleic acids are linked to one or more promoters, and nucleic acid encoding the heterologous polypeptide and a signal sequence for secretion of the heterologous polypeptide, which nucleic acid encoding the heterologous polypeptide is linked to a another promoter that is inducible, under certain conditions to produce a broth lysate; and recovering accumulated heterologous polypeptide from the broth lysate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 30 USPATFULL
ACCESSION NUMBER: 2000:153261 USPATFULL
TITLE: Platelet-activating factor acetylhydrolase
INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Auburn, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Edmonds, WA, United States
Tjoelker, Larry W., Kirkland, WA, United States
Wilder, Cheryl L., Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6146625		20001114
APPLICATION INFO.:	US 1998-10715		19980122 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-480658, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-318905, filed on 6 Oct 1994, now patented, Pat. No. US 5641669 which is a continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase

products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 30 USPATFULL
ACCESSION NUMBER: 2000:101869 USPATFULL
TITLE: Platelet-activating factor acetylhydrolase (PAF-AH) therapeutic uses
INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Auburn, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Edmonds, WA, United States
Tjoelker, Larry W., Kirkland, WA, United States
Wilder, Cheryl L., Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6099836		20000808
APPLICATION INFO.:	US 1998-100546		19980619 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-10715, filed on 22 Jan 1998 which is a continuation of Ser. No. US 1995-480658, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-318905, filed on 6 Oct 1994, now patented, Pat. No. US 5641669 which is a continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weber, Jon P.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events. Specifically disclosed are methods for the treatment of reperfusion injury using platelet-activating factor acetylhydrolase products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 30 USPATFULL
ACCESSION NUMBER: 2000:84056 USPATFULL
TITLE: Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
INVENTOR(S): Georgiou, George, Austin, TX, United States
Oiu, Ji, Austin, TX, United States
Bessette, Paul, Austin, TX, United States
Swartz, James, Menlo Park, CA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6083715 20000704
APPLICATION INFO.: US 1997-871483 19970609 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
ASSISTANT EXAMINER: Tung, Peter P.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 30 USPATFULL
ACCESSION NUMBER: 2000:57590 USPATFULL
TITLE: Protein kinases
INVENTOR(S): Hoekstra, Merl F., Shohomish, WA, United States
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060296		20000509
APPLICATION INFO.:	US 1994-185359		19940121 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-8001, filed on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-728783, filed on 3 Jul 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Bugaisky, Gabriele E.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 4312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Protein kinase mutant and wild-type genes encoding polypeptides of the class heretofore designated "casein kinase I" and useful in screening compositions which may affect DNA double-strand break repair activity are disclosed. Also disclosed are methods using the polynucleotides in cell-proliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 30 USPATFULL
ACCESSION NUMBER: 2000:40639 USPATFULL
TITLE: Platelet-activating factor acetylhydrolase
INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Redmond, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Edmonds, WA, United States
Tjoelker, Larry W., Kirkland, WA, United States
Wilder, Cheryl L., Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6045794		20000404
APPLICATION INFO.:	US 1999-328474		19990609 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-910041, filed on 12 Aug 1997 which is a continuation-in-part of Ser. No. US 1995-483232, filed on 7 Jun 1995, now patented, Pat. No. US 5656431 which is a continuation-in-part of Ser. No. US 1994-318905, filed on 6 Oct 1994, now patented, Pat. No. US 5641669 which is a continuation-in-part of Ser. No. US 1993-113803, filed on 6 Oct 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Hutson, Richard
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 4346
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 30 USPATFULL
ACCESSION NUMBER: 1999:137456 USPATFULL
TITLE: Platelet-activating factor acetylhydrolase
INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Redmond, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Edmonds, WA, United States
Tjoelker, Larry W., Kirkland, WA, United States
Wilder, Cheryl L., Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5977308		19991102
APPLICATION INFO.:	US 1997-910041		19970812 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-483232, filed on 7 Jun 1995, now patented, Pat. No. US 5656431 which is a continuation-in-part of Ser. No. US 1994-318905, filed on 6 Oct 1994, now patented, Pat. No. US 5641669 which is a continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: McGarry, Sean
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 4530

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 30 USPATFULL

ACCESSION NUMBER: 1998:154387 USPATFULL

TITLE: Antibodies specific for platelet-activating factor acetylhydrolase

INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Auburn, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Seattle, WA, United States
Tjoelker, Larry W., Bothell, WA, United States
Wilder, Cheryl L., Bellevue, WA, United States

PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5847088		19981208
APPLICATION INFO.:	US 1995-485938		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-318905, filed on 6 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Rees, Dianne
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3392

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 30 USPATFULL

ACCESSION NUMBER: 1998:91830 USPATFULL

TITLE: Process for bacterial production of polypeptides

INVENTOR(S): Joly, John C., San Mateo, CA, United States
Swartz, James R., Menlo Park, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789199		19980804
APPLICATION INFO.:	US 1996-741727		19961031 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-333912, filed on 3 Nov 1994, now patented, Pat. No. US 5639635

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
ASSISTANT EXAMINER: Lathrop, Brian
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is provided for producing a heterologous polypeptide in bacteria. This process comprises, in a first step, culturing bacterial cells that lack their native pstS gene and comprise nucleic acid encoding a PstS variant having an amino acid variation within the phosphate-binding region of the corresponding native PstS, nucleic acid encoding a DsbA or DsbC protein, nucleic acid encoding the heterologous polypeptide, a signal sequence for secretion of both the DsbA or DsbC protein and the heterologous polypeptide, an inducible promoter for the nucleic acid encoding the DsbA or DsbC protein, and an alkaline phosphatase promoter for the nucleic acid encoding the heterologous polypeptide. The nucleic acid encoding a PstS variant is under the transcriptional control of the wild-type pstS gene promoter. The second step of the process involves recovering the heterologous polypeptide from the periplasm or the culture medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 30 USPATFULL
ACCESSION NUMBER: 1998:57714 USPATFULL
TITLE: Protein kinases
INVENTOR(S): Hoekstra, Merl F., Shohomish, WA, United States
PATENT ASSIGNEE(S): Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756289		19980526
APPLICATION INFO.:	US 1995-453866		19950530 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-185359, filed on 21 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-8001, filed on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-728783, filed on 3 Jul 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Bugaisky, Gabriele E.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein kinase mutant and wild-type genes encoding polypeptides of the class heretofore designated "casein kinase I" and useful in screening compositions which may affect DNA double-strand break repair activity are disclosed. Also disclosed are methods using the polynucleotides in cell-proliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 30 USPATFULL
ACCESSION NUMBER: 97:117897 USPATFULL
TITLE: Methods of detecting platelet-activating factor acetylhydrolase using antibodies

INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Auburn, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Seattle, WA, United States
Tjoelker, Larry W., Bothell, WA, United States
Wilder, Cheryl L., Bellevue, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698403		19971216
APPLICATION INFO.:	US 1995-483140		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-318905, filed on 6 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Allen, Marianne P.
ASSISTANT EXAMINER: Duffy, Patricia A.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 30 USPATFULL
ACCESSION NUMBER: 97:104442 USPATFULL
TITLE: Protein kinases
INVENTOR(S): Hoekstra, Merl F., Snohomish, WA, United States
PATENT ASSIGNEE(S): Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5686412		19971111
APPLICATION INFO.:	US 1995-454097		19950530 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-185359, filed on 21 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-8001, filed on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-728783, filed on 3 Jul 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Bugaisky, Gabriele E.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Protein kinase mutant and wild-type genes encoding polypeptides of the class heretofore designated "casein kinase I" and useful in screening compositions which may affect DNA double-strand break repair activity

are disclosed. Also disclosed are methods using the polynucleotides in cell-proliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 30 USPATFULL
ACCESSION NUMBER: 97:70874 USPATFULL
TITLE: Platelet-activating factor acetylhydrolase
INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Auburn, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Edmonds, WA, United States
Tjoelker, Larry W., Kirkland, WA, United States
Wilder, Cheryl L., Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656431		19970812
APPLICATION INFO.:	US 1995-483232		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-318905, filed on 6 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliot, George C.
ASSISTANT EXAMINER: McGarry, Sean
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3082
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 30 USPATFULL
ACCESSION NUMBER: 97:54121 USPATFULL
TITLE: Platelet-activating factor acetylhydrolase
INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States
Eberhardt, Christine D., Auburn, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai Le, Seattle, WA, United States
Tjoelker, Larry W., Bothell, WA, United States
Wilder, Cheryl L., Bellevue, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5641669		19970624
APPLICATION INFO.:	US 1994-318905		19941006 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.

ASSISTANT EXAMINER: Rees, Dianne
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 18 OF 30 USPATFULL
ACCESSION NUMBER: 97:51887 USPATFULL
TITLE: Process for bacterial production of polypeptides
INVENTOR(S): Joly, John C., San Mateo, CA, United States
Swartz, James R., Menlo Park, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5639635		19970617	
APPLICATION INFO.:	US 1994-333912		19941103	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hendricks, Keith D.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for producing a heterologous polypeptide in bacteria, which process comprises:

(a) culturing bacterial cells, which cells comprise nucleic acid encoding a DsbA or DsbC protein, nucleic acid encoding the heterologous polypeptide, a signal sequence for secretion of both the DsbA or DsbC protein and the heterologous polypeptide, and an inducible promoter for both the nucleic acid encoding the DsbA or DsbC protein and the nucleic acid encoding the heterologous polypeptide, under conditions whereby expression of the nucleic acid encoding the DsbA or DsbC protein is induced prior to induction of the expression of the nucleic acid encoding the heterologous polypeptide, and under conditions whereby either both the heterologous polypeptide and the DsbA or DsbC protein are secreted into the periplasm of the bacteria or the heterologous polypeptide is secreted into the medium in which the bacterial cells are cultured; and

(b) recovering the heterologous polypeptide from the periplasm or the culture medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 19 OF 30 USPATFULL
ACCESSION NUMBER: 97:15958 USPATFULL
TITLE: Methods of detecting lesions in the platelet-activating factor acetylhydrolase gene
INVENTOR(S): Cousens, Lawrence S., Oakland, CA, United States

Eberhardt, Christine D., Auburn, WA, United States
Gray, Patrick, Seattle, WA, United States
Trong, Hai L., Seattle, WA, United States
Tjoelker, Larry W., Bothell, WA, United States
Wilder, Cheryl L., Bellevue, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5605801		19970225
APPLICATION INFO.:	US 1995-478465		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-318905, filed on 6 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-133803, filed on 6 Oct 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Whisenant, Ethan
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events. Furthermore provided are therapeutic and diagnostic methods using such polynucleotide sequences and platelet-activating factor acethylhydrolase products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 30 USPATFULL
ACCESSION NUMBER: 97:1345 USPATFULL
TITLE: G protein-coupled receptor kinase GRK6
INVENTOR(S): Chantry, David, Seattle, WA, United States
Gray, Patrick W., Seattle, WA, United States
Hoekstra, Merl F., Snohomish, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5591618		19970107
APPLICATION INFO.:	US 1995-454439		19950530 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-221817, filed on 31 Mar 1994, now patented, Pat. No. US 5532151 which is a continuation-in-part of Ser. No. US 1993-123932, filed on 17 Sep 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles
ASSISTANT EXAMINER: Kim, Hyosuk
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides purified and isolated polynucleotide

sequences encoding the novel G protein-coupled receptor kinase designated GRK6. Also provided by the invention are methods and materials for the recombinant production of GRK6 enzyme and methods for identifying compounds which modulate the protein kinase activity of GRK6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 21 OF 30 USPATFULL

ACCESSION NUMBER:	96:58128 USPATFULL
TITLE:	G protein-coupled receptor kinase GRK6
INVENTOR(S):	Chantry, David, Seattle, WA, United States Gray, Patrick W., Seattle, WA, United States Hoekstra, Merl F., Snohomish, WA, United States
PATENT ASSIGNEE(S):	ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5532151		19960702
APPLICATION INFO.:	US 1994-221817		19940331 (8)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-123932, filed on 17 Sep 1993, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Wax, Robert A.
ASSISTANT EXAMINER:	Kim, Hyosuk
LEGAL REPRESENTATIVE:	Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT:	1313

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides purified and isolated polynucleotide sequences encoding the novel G protein-coupled receptor kinase designated GRK6. Also provided by the invention are methods and materials for the recombinant production of GRK6 enzyme and methods for identifying compounds which modulate the protein kinase activity of GRK6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 22 OF 30 USPATFULL

ACCESSION NUMBER:	96:38810 USPATFULL
TITLE:	Plasmid vectors and GRAS microorganisms promoting ice nucleation
INVENTOR(S):	Hottinger, Herbert, Blonay, Switzerland Niederberger, Peter, Epalinges, Switzerland Pridmore, David, Pully, Switzerland Staeger-Roos, Ursula, Cheong Ju, Korea, Republic of
PATENT ASSIGNEE(S):	Nestec S.A., Vevey, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5514586		19960507
APPLICATION INFO.:	US 1992-963290		19921019 (7)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-596203, filed on 11 Oct 1990, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1989-23998	19891025

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted

PRIMARY EXAMINER: Mosher, Mary E.
LEGAL REPRESENTATIVE: Vogt & O'Donnell
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 1401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Ice nucleation is promoted in an ingestible biological material by treating the material with an ice-nucleating protein carried by a yeast or lactococcal GRAS microorganism, or a fraction thereof, transformed by a plasmid vector carrying a gene coding for the ice-nucleating protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 23 OF 30 USPATFULL
ACCESSION NUMBER: 95:13769 USPATFULL
TITLE: Lipase from Pseudomonas mendocina having cutinase activity
INVENTOR(S): Gray, Gregory L., Boise, ID, United States
Power, Scott D., San Bruno, CA, United States
Poulose, Ayrookaran J., Belmont, CA, United States
PATENT ASSIGNEE(S): Genencor, Inc., Rochester, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5389536		19950214
APPLICATION INFO.:	US 1991-705052		19910523 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-629308, filed on 18 Dec 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-465532, filed on 17 Jan 1990, now abandoned which is a continuation of Ser. No. US 1987-107902, filed on 19 Oct 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-932959, filed on 19 Nov 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Knode, Marian
LEGAL REPRESENTATIVE: Horn, Margaret A.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially enzymatically pure hydrolase is provided which is secreted by and isolatable from Pseudomonas mendocina ATCC 53552. Cloning the gene expressing the hydrolase into a suitable expression vector and culturing, such as fermenting the E. coli strain JM101 harboring a plasmid designated pSNtacII, has been found to provide surprisingly high yields of the hydrolase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 24 OF 30 USPATFULL
ACCESSION NUMBER: 94:86324 USPATFULL
TITLE: Selection and method of making enzymes for perhydrolysis system and for altering substrate specificity, specific activity and catalytic efficiency
INVENTOR(S): Poulouse, Ayrookaran J., San Bruno, CA, United States
PATENT ASSIGNEE(S): Genecor, Inc., Rochester, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5352594 19941004
APPLICATION INFO.: US 1992-908596 19920630 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-668311, filed on 11 Mar 1991, now abandoned which is a continuation of Ser. No. US 1988-287316, filed on 19 Dec 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-86869, filed on 21 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-905363, filed on 9 Sep 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-858594, filed on 30 Apr 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-614612, filed on 29 May 1984, now patented, Pat. No. US 4760025 And a continuation-in-part of Ser. No. US 1984-614615, filed on 29 May 1984, now abandoned And a continuation-in-part of Ser. No. US 1984-614617, filed on 29 May 1984, now abandoned And a continuation-in-part of Ser. No. US 1984-614491, filed on 29 May 1984, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Prouty, Rebecca
LEGAL REPRESENTATIVE: Horn, Margaret A.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 931
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods of making and selecting esterase enzymes having an improved perhydrolysis to hydrolysis ratio, and varying K.sub.cat, K.sub.m, and K.sub.cat /K.sub.m and substrate specificity. Such enzymes are useful in peracid bleaching systems and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 25 OF 30 USPATFULL
ACCESSION NUMBER: 92:33621 USPATFULL
TITLE: Enzymatic peracid bleaching system with modified enzyme
INVENTOR(S): Poulose, Ayrookaram J., San Bruno, CA, United States
Anderson, Susan A., Menlo Park, CA, United States
PATENT ASSIGNEE(S): The Clorox Company, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5108457		19920428
APPLICATION INFO.:	US 1988-286353		19881219 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-932717, filed on 19 Nov 1986, now patented, Pat. No. US 5030240 which is a continuation-in-part of Ser. No. US 1986-872252, filed on 9 Jun 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartz, Richard A.
ASSISTANT EXAMINER: Mosher, Mary E.
LEGAL REPRESENTATIVE: Majestic, Parsons, Siebert & Hsue
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An enzymatic perhydrolysis system, useful for bleaching, has a novel enzyme, a substrate, and a source of hydrogen peroxide, and provides in

situ formation of peracid in aqueous solution. The substrate is selected for enzyme catalyzed reaction, and preferably is an acylglycerol with two or three fatty acid chains. The enzyme is hydrolytically and perhydrolytically active even in the presence of anionic surfactants, has lipase activity, and is modified from an enzyme isolatable from Pseudomonas putida ATCC 53552.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 30 USPATFULL

ACCESSION NUMBER:	91:56853 USPATFULL
TITLE:	Metabolic pathway engineering to increase production of ascorbic acid intermediates
INVENTOR(S):	Anderson, Stephen, San Mateo, CA, United States Lazarus, Robert A., Millbrae, CA, United States Miller, Harvey I., Pleasant Hill, CA, United States Stafford, R. Kevin, San Mateo, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5032514		19910716	
APPLICATION INFO.:	US 1988-229598		19880808	(7)
DISCLAIMER DATE:	20080416			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Robinson, Douglas W.			
ASSISTANT EXAMINER:	Knode, Marian C.			
LEGAL REPRESENTATIVE:	Dreger, Ginger R.			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 19 Drawing Page(s)			
LINE COUNT:	1417			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In recombinant microorganisms which were rendered capable of converting 2,5-diketo-D-gluconic acid (2,5-DKG) to 2-keto-L-gulonic acid (2-KLG) by transfer of genetic material, the secondary metabolites and metabolic pathways leading to the metabolic diversion of 2-KLG and 2,5-DKG were determined, and the diversion of 2-KLG to L-iodonic acid (IA) or of 2,5-DKG to 5-keto-D-gluconate (5-KDH) was blocked.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 30 USPATFULL

ACCESSION NUMBER:	91:54379 USPATFULL
TITLE:	Enzymatic peracid bleaching system
INVENTOR(S):	Wiersema, Richard J., Tracy, CA, United States Stanislowski, Anna G., Walnut Creek, CA, United States Gray, Gregory L., So. San Francisco, CA, United States Poulose, Ayrookaram J., San Bruno, CA, United States Power, Scott D., San Bruno, CA, United States
PATENT ASSIGNEE(S):	The Clorox Company, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5030240		19910709	
APPLICATION INFO.:	US 1986-932717		19861119	(6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1986-872252, filed on 9 Jun 1986, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Schwartz, Richard A.			

ASSISTANT EXAMINER: Mosher, M. E.
LEGAL REPRESENTATIVE: Majestic, Parsons Siebert & Hsue
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 11
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An enzymatic perhydrolysis system, useful for bleaching, has a novel enzyme, a substrate, and a source of hydrogen peroxide, and provides in situ formation of peracid in aqueous solution. The substrate is selected for enzyme catalyzed reaction, and preferably is an acylglycerol with two or three fatty acid chains. The enzyme is hydrolytically and perhydrolytically active even in the presence of anionic surfactants, has lipase activity, and is isolatable from Pseudomonas putida ATCC 53552.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1985:608117 CAPLUS
DOCUMENT NUMBER: 103:208117
TITLE: Expression of cell wall degrading proteins and host cells harboring DNA encoding such protein
INVENTOR(S): Wetzel, Ronald Burnell
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 155189	A2	19850918	EP 1985-301827	19850315
EP 155189	A3	19870916		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 60221077	A2	19851105	JP 1985-53206	19850316
PRIORITY APPLN. INFO.:			US 1984-590138	19840316
			US 1984-649786	19840911

AB A method is presented to induce a recombinant cell culture to produce lysozyme [9001-63-2] in which the viability of the cells is not inhibited or destroyed. Thus, the phage T4 lysozyme gene was isolated and cloned into plasmid pKCEAtetRXAP to yield the plasmid pT4lysXHtrp. A 3-way ligation between fragments of phGH207-1, pT4lysXHtrp, and pBR322 yielded a plasmid, pT4lysXRtrp.DELTA.5', which contained the 5' portion of the lysozyme gene with a 97-base deletion in the 5'-untranslated region. The 5'-end of the lysozyme gene from plasmid pT4lysXRtrp.DELTA.5' was ligated to a fragment of pT4lysXHtrp, which contained the 3' portion of the gene, and was put under the control of the **tacII promoter** of plasmid phGH907tacII to yield pT4lystacII. Escherichia coli Transformed with pT4lystacII were grown to the late log phase, induced with the addn. of isopropyl-.beta.-D-thiogalactoside, harvested by centrifugation, and frozen. Frozen cells from 0.5 L of culture were lysed upon thawing. The yield of protein was 4 mg.

L2 ANSWER 29 OF 30 USPATFULL
ACCESSION NUMBER: 85:65304 USPATFULL
TITLE: Microbial hybrid promoters
INVENTOR(S): DeBoer, Herman A., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION:	US 4551433	19851105
APPLICATION INFO.:	US 1982-338397	19820111 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1981-264306, filed on 18 May 1981, now abandoned And a continuation-in-part of Ser. No. US 1981-328174, filed on 7 Dec 1981, now abandoned	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wiseman, Thomas G.	
ASSISTANT EXAMINER:	Martinell, James	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	8	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	1015	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel microbial hybrid promoters and their use to direct the microbial expression of heterologous genes are described. Such promoters are selectively and functionally constructed by recombinant techniques, utilizing the discovery that certain DNA regions of given promoters are responsible for particularly advantageous functional properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:	1983:155825 CAPLUS
DOCUMENT NUMBER:	98:155825
TITLE:	Construction of three hybrid promoters and their properties in Escherichia coli
AUTHOR(S):	De Boer, Herman; Heyneker, Herbert; Comstock, Lisa; Wieland, Alice; Vasser, Mark; Horn, Thomas
CORPORATE SOURCE:	Mol. Biol. Dep., Genentech, Inc., South San Francisco, CA, USA
SOURCE:	Miami Winter Symposia (1982), 19(From Gene Protein: Transl. Biotechnol.), 309-27 CODEN: MIWSAE; ISSN: 0097-0808
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Three hybrid promoters which are functional in Escherichia coli are described. In the case of the 1st hybrid promoter (tacI), sequences upstream of position -20 were derived from the trp promoter and sequences downstream of position -20 were derived from the lac-UV5 promoter. This hybrid promoter is 7-fold stronger than the lac-UV5 promoter. It can be repressed by the lac-repressor and induced by isopropyl-.beta.-D-thiogalactoside (IPTG) [367-93-1]. In the case of the 2nd hybrid promoter (tacII), the DNA sequences upstream of the HpaI site (which is located in the Pribnow box of the trp-promoter) were fused to a synthetic DNA fragment of 46 base pairs. The sequence of the synthetic fragment creates a new Pribnow-box which is followed by the lac-operator. Downstream from the lac-operator are nucleotides that code for a Shine-Dalgarno sequence. The Shine-Dalgarno sequence is flanked by 2 restriction sites, which allows the exchange of different Shine-Dalgarno sequences. Thus, an inducible promoter with a portable Shine Dalgarno sequence was constructed; it forms an active ribosome binding site when fused to the start codon of a foreign gene. The **tacII promoter** is as efficient as the tacI promoter. The 3rd hybrid promoter (rac5-16) is a hybrid between the rrnB promoter and the lacUV5 promoter. Its structure resembles that of the tacI promoter. At the junction, in the area of -20, 3 unique restriction sites were introduced. This makes it possible to change the distance and the nucleotide sequence between the -35 area and the -10 area (the Pribnow box).

=> s trp()lac hybrid promoter

L3 72 TRP(W) LAC HYBRID PROMOTER

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 44 DUP REM L3 (28 DUPLICATES REMOVED)

=> d l4 ibib abs tot

L4 ANSWER 1 OF 44 USPATFULL

ACCESSION NUMBER:	2002:295304 USPATFULL
TITLE:	Tumor necrosis factor inhibitory protein and its purification
INVENTOR(S):	Wallach, David, Rehovot, ISRAEL Engelmann, Hartmut, Munchen, GERMANY, FEDERAL REPUBLIC OF Aderka, Dan, Holon, ISRAEL Rubinstein, Menachem, Givat Schmuel, ISRAEL
PATENT ASSIGNEE(S):	Yeda Research and Development Company Ltd., Rehovot, ISRAEL, 76 100 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165354	A1	20021107
APPLICATION INFO.:	US 2002-36452	A1	20020107 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-414609, filed on 8 Oct 1999, PENDING Division of Ser. No. US 1995-474691, filed on 7 Jun 1995, PATENTED Division of Ser. No. US 1992-876828, filed on 30 Apr 1992, PATENTED Continuation of Ser. No. US 1988-243092, filed on 12 Sep 1988, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1987-83878	19870913

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Page(s)
LINE COUNT:	967

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant DNA encoding Tumor Necrosis Factor (TNF) Inhibitory Protein, or an active fragment thereof, is obtained. The TNF Inhibitory Protein has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF by eliminating TNF from the body, and to reduce the cytotoxic activity of TNF by binding to TNF and thereby to inhibit the binding of TNF to its receptors. The DNA may be in an expression vector. Host cells transfected with such an expression vector may be used to produce the TNF Inhibitory Protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 44 USPATFULL

ACCESSION NUMBER:	2002:295118 USPATFULL
TITLE:	Tumor necrosis factor inhibitory protein and its purification
INVENTOR(S):	Wallach, David, Rehovot, ISRAEL Engelmann, Hartmut, Munchen, GERMANY, FEDERAL REPUBLIC OF Aderka, Dan, Holon, ISRAEL

Rubinstein, Menachem, Givat Schmuel, ISRAEL
PATENT ASSIGNEE(S): Yeda Research Development Company Ltd., Rehovot, ISRAEL, 76 100 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165163	A1	20021107
APPLICATION INFO.:	US 2002-36434	A1	20020107 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-414609, filed on 8 Oct 1999, PENDING Division of Ser. No. US 1995-474691, filed on 7 Jun 1995, GRANTED, Pat. No. US 5981701 Division of Ser. No. US 1992-876828, filed on 30 Apr 1992, GRANTED, Pat. No. US 5695953 Continuation of Ser. No. US 1988-243092, filed on 12 Sep 1988, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1987-83878	19870913

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF by eliminating TNF from the body, and to reduce the cytotoxic activity of TNF by binding to TNF and thereby to inhibit the binding of TNF to its receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 44 USPATFULL
ACCESSION NUMBER: 2002:206761 USPATFULL
TITLE: TNF binding ligands and antibodies
INVENTOR(S): Wallach, David, Rehovot, ISRAEL
Bigda, Jacek, Gdansk, POLAND
Beletsky, Igor, Pushino, RUSSIAN FEDERATION
Mett, Igor, Rehovot, ISRAEL
Engelmann, Hartmut, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Yeda Research and Development Co., Ltd., Rehovot, ISRAEL, 76100 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002111462	A1	20020815
APPLICATION INFO.:	US 2001-800908	A1	20010308 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-477347, filed on 7 Jun 1995, PATENTED Continuation-in-part of Ser. No. US 1992-930443, filed on 19 Aug 1992, PENDING Continuation-in-part of Ser. No. US 1995-450972, filed on 25 May 1995, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1989-90339	19890518
	IL 1989-91229	19890806

	IL 1990-94039	19900406
	IL 1992-103051	19920903
	IL 1993-106271	19930708

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., PATENT AND TRADEMARK CAUSES, SUITE 300, 624 NINTH STREET, N.W., WASHINGTON, DC, 20001-5303
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p75 TNF receptor, which loop consists of the amino acid sequence Cys-185 to Thr-201 of SEQ ID NO:3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 44 USPATFULL
ACCESSION NUMBER: 2002:8243 USPATFULL
TITLE: Plasmids for construction of eukaryotic viral vectors
INVENTOR(S): McVey, Duncan L., Derwood, MD, UNITED STATES
Brough, Douglas E., Olney, MD, UNITED STATES
Kovesdi, Imre, Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): GenVec, Inc., Gaithersburg, MD, UNITED STATES, 20878 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004242	A1	20020110
	US 6475757	B2	20021105
APPLICATION INFO.:	US 2001-905758	A1	20010713 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-513803, filed on 25 Feb 2000, PENDING Continuation of Ser. No. WO 1998-US20009, filed on 23 Sep 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-59824P	19970923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1109
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a dual selection cassette (DSC) comprising first and second DNA segments having homology to a eukaryotic viral vector, positive and negative selection genes, each operably linked to their own promoter, and one or more unique restriction enzyme sites (URES) or sitey-directed homologous recombination sites. The present invention also provides a plasmid, pN/P, comprising an independent positive selection marker gene, an origin of replication, and a dual selection cassette. The dual selection cassette and pN/P plasmid can be used to produce eukaryotic gene transfer vectors without requiring temporally-linked double recombination events or the use of specialized bacterial strains that allow the replication of plasmids

comprising defective origins of replication. This method usefully increases the ratio of desired to undesired plasmid and vector constructs. Additionally, this invention provides a method for the creation of eukaryotic viral vector libraries.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 44 USPATFULL
ACCESSION NUMBER: 2002:8227 USPATFULL
TITLE: Soluble LDL receptor, its production and use
INVENTOR(S): Rubinstein, Menachem, Givat Schmuel, ISRAEL
Novick, Daniela, Rehovot, ISRAEL
Tal, Nathan, Rehovot, ISRAEL
Fischer, Dina G., Rehovot, ISRAEL
PATENT ASSIGNEE(S): Yeda Research and Developmemt Co. Ltd., Rehovot, ISRAEL (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004226	A1	20020110
APPLICATION INFO.:	US 2001-824637	A1	20010404 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-485128, filed on 7 Jun 1995, PENDING Division of Ser. No. US 1993-92817, filed on 19 Jul 1993, GRANTED, Pat. No. US 5496926 Continuation-in-part of Ser. No. US 1993-4863, filed on 19 Jan 1993, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-100696	19920119
	IL 1992-102915	19920823

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 1692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA encoding a soluble LDL receptor protein, is provided, as are vectors, cell lines and processes for the production of the protein, mutein or fragment. The soluble LDL receptor protein, and its muteins and fragments, are useful in protection of mammals against viral infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 44 USPATFULL
ACCESSION NUMBER: 2002:297683 USPATFULL
TITLE: Tumor necrosis factor inhibitory protein and its purification
INVENTOR(S): Wallach, David, Rehovot, ISRAEL
Engelmann, Hartmut, Munich, GERMANY, FEDERAL REPUBLIC OF
Aderka, Dan, Holon, ISRAEL
Rubinstein, Menachem, Givat Schmuel, ISRAEL
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, ISRAEL (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479632	B1	20021112
APPLICATION INFO.:	US 1999-414609		19991008 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-474691, filed on 7 Jun 1995, now patented, Pat. No. US 5981701, issued on 9 Nov 1999 Division of Ser. No. US 1992-876828, filed on 30 Apr 1992, now patented, Pat. No. US 5695953, issued on 9 Dec 1997 Continuation of Ser. No. US 1988-243092, filed on 12 Sep 1988, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: Jiang, Dong
LEGAL REPRESENTATIVE: Browdy and Neimark, P.L.L.C.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,7
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF.

TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 44 USPATFULL
ACCESSION NUMBER: 2002:238852 USPATFULL
TITLE: Synthetic molecules that specifically react with target sequences
INVENTOR(S): Tsien, Roger Y., La Jolla, CA, United States
Griffin, B. Albert, Del Mar, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451569	B1	20020917
APPLICATION INFO.:	US 1999-372338		19990811 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-955859, filed on 21 Oct 1997, now patented, Pat. No. US 6008378
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 44 USPATFULL
ACCESSION NUMBER: 2002:122247 USPATFULL
TITLE: TNF receptor action modulation
INVENTOR(S): Wallach, David, Rehovot, ISRAEL
Brakebusch, Cord, Braunschweig, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, ISRAEL (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6395267	B1	20020528	
APPLICATION INFO.:	US 1993-54970		19930503	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-101769	19920503

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Browdy and Neimark, P.L.L.C.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of modulating signal transduction and/or cleavage in Tumor Necrosis Factor Receptors (TNF-Rs) is provided. Peptides or other molecules may interact either with the receptor itself, or with effector proteins interacting with the receptor, thus modulating the normal functioning of the TNF-Rs. Such peptides or other molecules may be employed for prophylactic and therapeutic applications in TNF associated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 44 USPATFULL
ACCESSION NUMBER: 2002:75194 USPATFULL
TITLE: Metabolic selection methods
INVENTOR(S): Hoch, James, La Jolla, CA, United States
Dartois, Veronique, San Diego, CA, United States
PATENT ASSIGNEE(S): MicroGenomics, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6368793	B1	20020409	
APPLICATION INFO.:	US 1998-172952		19981014	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McGarry, Sean
ASSISTANT EXAMINER: Lacourciere, Karen A
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 3433
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates in part to methods for screening for novel enzymatic pathways in environmental samples using metabolic selection strategies, and the isolation of the genes and proteins that make up these pathways.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 44 USPATFULL
ACCESSION NUMBER: 2002:70096 USPATFULL
TITLE: Soluble LDL receptor, its production and use
INVENTOR(S): Rubinstein, Menachem, Givat Shmuel, ISRAEL
Novick, Daniela, Rehovot, ISRAEL

Tal, Nathan, Rehovot, ISRAEL
Fischer, Dina G., Rehovot, ISRAEL
PATENT ASSIGNEE(S): Yeda Research and Development Company, Limited, Rehovot, ISRAEL (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6365713	B1	20020402
APPLICATION INFO.:	US 1995-485128		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-92817, filed on 19 Jul 1993, now patented, Pat. No. US 5496926
Continuation-in-part of Ser. No. US 1993-4863, filed on 19 Jan 1993, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-100696	19920119
	IL 1992-102915	19920823

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mertz, Prema
ASSISTANT EXAMINER: Murphy, Joseph F.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A soluble LDL receptor protein is provided. It can be isolated from cells that have been treated with an interferon, isolated from the urine of healthy human individuals or produced by recombinant techniques. The soluble LDL receptor protein is useful in protection of mammals against viral infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 44 USPATFULL
ACCESSION NUMBER: 2001:226464 USPATFULL
TITLE: Plasmids for construction of eukaryotic viral vectors
INVENTOR(S): McVey, Duncan L., Derwood, MD, United States
Brough, Douglas E., Olney, MD, United States
Kovesdi, Imre, Rockville, MD, United States
PATENT ASSIGNEE(S): GenVec, Inc., Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6329200	B1	20011211
APPLICATION INFO.:	US 2000-513803		20000225 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US20009, filed on 23 Sep 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-59824P	19970923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Schwartzman, Robert A.
ASSISTANT EXAMINER: Davis, Katharine I
LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1102

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a dual selection cassette (DSC) comprising first and second DNA segments having homology to a eukaryotic viral vector, positive and negative selection genes, each operably linked to their own promoter, and one or more unique restriction enzyme sites (URES) or site-directed homologous recombination sites. The present invention also provides a plasmid, pN/P, comprising an independent positive selection marker gene, an origin of replication, and a dual selection cassette. The dual selection cassette and pN/P plasmid can be used to produce eukaryotic gene transfer vectors without requiring temporally-linked double recombination events or the use of specialized bacterial strains that allow the replication of plasmids comprising defective origins of replication. This method usefully increases the ratio of desired to undesired plasmid and vector constructs. Additionally, this invention provides a method for the creation of eukaryotic viral vector libraries.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 44 USPATFULL

ACCESSION NUMBER:	2001:157797 USPATFULL			
TITLE:	Method for screening compounds for inhibiting bacterial attachment to host cell receptors			
INVENTOR(S):	Wu, Xue-Ru, Woodside, NY, United States Sun, Tung-Tien, Scarsdale, NY, United States			
PATENT ASSIGNEE(S):	New York University, New York, NY, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6290959	B1	20010918	
APPLICATION INFO.:	US 1997-957130		19971024	(8)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 1996-29762P		19961024	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Graser, Jennifer E.			
ASSISTANT EXAMINER:	Hines, Ja-Na A.			
LEGAL REPRESENTATIVE:	Browdy and Neimark			
NUMBER OF CLAIMS:	5			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 9 Drawing Page(s)			
LINE COUNT:	2067			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Uroplakins Ia and Ib are the major urothelial receptors of type 1 fimbriated microorganisms. These uroplakins are used to screen compounds for treating urinary tract infections by testing if the compounds inhibit bacterial adhesion to the uroplakins. Additionally, compounds which inhibit adhesion of microorganisms expressing type 1 fimbriae, such as Tamm-Horsfall protein, are used to treat or inhibit infection by these microorganisms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 44 USPATFULL

ACCESSION NUMBER:	2001:71680 USPATFULL
TITLE:	TNF ligands
INVENTOR(S):	Wallach, David, Rehovot, Israel Bigda, Jacek, Gdansk, Poland Beletsky, Igor, Pushino, Russian Federation Mett, Igor, Rehovot, Israel Engelmann, Hartmut, Munich, Germany, Federal Republic

of
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232446	B1	20010515
APPLICATION INFO.:	US 1995-477347		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-450972, filed on 25 May 1995, now abandoned Continuation-in-part of Ser. No. US 1992-930443, filed on 19 Aug 1992 Continuation of Ser. No. US 1990-524263, filed on 16 May 1990, now abandoned Continuation of Ser. No. US 1993-115685, filed on 3 Sep 1993, now abandoned

PRIORITY INFORMATION:	NUMBER	DATE
	IL 1989-90339	19890518
	IL 1989-91229	19890806
	IL 1990-94039	19900406
	IL 1992-103051	19920903
	IL 1993-106271	19930708

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 1188
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p75 TNF receptor, which loop consists of the amino acid sequence Cys-185 to Thr-201 of SEQ ID NO:3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 44 USPATFULL
ACCESSION NUMBER: 2001:29353 USPATFULL
TITLE: Expression systems for preparation of polypeptides in prokaryotic cells
INVENTOR(S): Rose, Timothy M., Seattle, WA, United States
Bruce, A. Gregory, Seattle, WA, United States
PATENT ASSIGNEE(S): Oncogen, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6194200	B1	20010227
APPLICATION INFO.:	US 1992-993482		19921218 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-750710, filed on 20 Aug 1991, now abandoned Division of Ser. No. US 1988-264098, filed on 28 Oct 1988, now abandoned Continuation-in-part of Ser. No. US 1988-240768, filed on 2 Sep 1988, now abandoned Continuation-in-part of Ser. No. US 1987-115139, filed on 30 Oct 1987, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Guzo, David
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP

NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 2862
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Expression cassettes for enhanced expression and production of a polypeptide of interest in prokaryotic cells are provided. The expression cassettes provide for production of the polypeptide of interest so that such polypeptide can either be secreted from the host cell in an active conformation or conveniently processed and renatured to a functional state. Preferably, the polypeptide of interest is expressed as a fusion protein, particularly fused to a leader sequence from a highly expressed bacterial or bacteriophage gene. The polypeptide of interest may subsequently be cleaved from the leader sequence and refolded, or used as a fusion protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 44 USPATFULL
ACCESSION NUMBER: 2000:84027 USPATFULL
TITLE: Increased production of Thermus aquaticus DNA polymerase in E. coli
INVENTOR(S): Sullivan, Mark A., Rochester, NY, United States
PATENT ASSIGNEE(S): Johnson & Johnson Clinical Diagnostic Systems, Inc., Rochester, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6083686		20000704	
APPLICATION INFO.:	US 1990-602848		19901026	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Guzo, David
ASSISTANT EXAMINER: Shuman, John
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 894
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The Thermus aquaticus gene encoding a thermostable DNA polymerase (Taq Pol) is altered in the N-terminus-encoding region to provide mutant genes with improved expression in E. coli.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 44 USPATFULL
ACCESSION NUMBER: 2000:50521 USPATFULL
TITLE: Methods of using synthetic molecules and target sequences
INVENTOR(S): Tsien, Roger Y., La Jolla, CA, United States
Griffin, B. Albert, Del Mar, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6054271		20000425	
APPLICATION INFO.:	US 1997-955050		19971021	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)

LINE COUNT: 1417
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features biarsenical molecules and target sequences that specifically react with the biarsenical molecules. Methods of using the biarsenical molecules, tetraarsenical molecules and the target sequences are included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 44 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2000143746 MEDLINE
DOCUMENT NUMBER: 20143746 PubMed ID: 10678947
TITLE: Identification of novel serine/threonine protein phosphatases in Trypanosoma cruzi: a potential role in control of cytokinesis and morphology.
AUTHOR: Orr G A; Werner C; Xu J; Bennett M; Weiss L M; Takvorkan P; Tanowitz H B; Wittner M
CORPORATE SOURCE: Departments of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.. orr@aecom.yu.edu
CONTRACT NUMBER: AI 12770 (NIAID)
HD 27569 (NICHD)
P30-CA13330 (NCI)
+
SOURCE: INFECTION AND IMMUNITY, (2000 Mar) 68 (3) 1350-8. Journal code: 0246127. ISSN: 0019-9567.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200003
ENTRY DATE: Entered STN: 20000327
Last Updated on STN: 20020924
Entered Medline: 20000316

AB We cloned two novel Trypanosoma cruzi proteins by using degenerate oligonucleotide primers prepared against conserved domains in mammalian serine/threonine protein phosphatases 1, 2A, and 2B. The isolated genes encoded proteins of 323 and 330 amino acids, respectively, that were more homologous to the catalytic subunit of human protein phosphatase 1 than to those of human protein phosphatase 2A or 2B. The proteins encoded by these genes have been tentatively designated TcPP1alpha and TcPP1beta. Northern blot analysis revealed the presence of a major 2.3-kb mRNA transcript hybridizing to each gene in both the epimastigote and metacyclic trypomastigote developmental stages. Southern blot analysis suggests that each protein phosphatase 1 gene is present as a single copy in the T. cruzi genome. The complete coding region for TcPP1beta was expressed in Escherichia coli by using a vector, pTACTAC, with the **trp-lac hybrid promoter**. The recombinant protein from the TcPP1beta construct displayed phosphatase activity toward phosphorylase a, and this activity was preferentially inhibited by calyculin A (50% inhibitory concentration [IC(50)], approximately 2 nM) over okadaic acid (IC(50), approximately 100 nM). Calyculin A, but not okadaic acid, had profound effects on the in vitro replication and morphology of T. cruzi epimastigotes. Low concentrations of calyculin A (1 to 10 nM) caused growth arrest. Electron microscopic studies of the calyculin A-treated epimastigotes revealed that the organisms underwent duplication of organelles, including the flagellum, kinetoplast, and nucleus, but were incapable of completing cell division. At concentrations higher than 10 nM, or upon prolonged incubation at lower concentrations, the epimastigotes lost their characteristic elongated spindle shape and had a more rounded morphology. Okadaic acid at concentrations up to 1 microM did not result in growth arrest or morphological alterations to T. cruzi epimastigotes. Calyculin A, but not okadaic acid, was also a potent inhibitor of the dephosphorylation of (32)P-labeled phosphorylase a by T.

cruzi epimastigotes and metacyclic trypomastigote extracts. These inhibitor studies suggest that in T. cruzi, type 1 protein phosphatases are important for the completion of cell division and for the maintenance of cell shape.

L4 ANSWER 18 OF 44 USPATFULL

ACCESSION NUMBER:	1999:170770 USPATFULL
TITLE:	Synthetic molecules that specifically react with target sequences
INVENTOR(S):	Tsien, Roger Y., La Jolla, CA, United States Griffin, B. Albert, Del Mar, CA, United States
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6008378		19991228
APPLICATION INFO.:	US 1997-955859		19971021 (8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Owens, Amelia
LEGAL REPRESENTATIVE:	Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.
NUMBER OF CLAIMS:	39
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT:	1409

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 44 USPATFULL

ACCESSION NUMBER:	1999:142108 USPATFULL
TITLE:	Tumor necrosis factor inhibitory protein and its purification
INVENTOR(S):	Wallach, David, Rehovot, Israel Engelmann, Hartmut, Munich, Germany, Federal Republic of Aderka, Dan, Holon, Israel Rubinstein, Menachem, Givat Schmuel, Israel
PATENT ASSIGNEE(S):	Yeda Research and Development Company Limited, Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981701		19991109
APPLICATION INFO.:	US 1995-474691		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-876828, filed on 30 Apr 1992, now patented, Pat. No. US 5695953 which is a continuation of Ser. No. US 1988-243092, filed on 12 Sep 1988, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1987-83878	19870913

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Draper, Garnette D.
LEGAL REPRESENTATIVE:	Browdy and Neimark
NUMBER OF CLAIMS:	3

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1002
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 44 USPATFULL
ACCESSION NUMBER: 1999:89051 USPATFULL
TITLE: Target sequences for synthetic molecules
INVENTOR(S): Tsien, Roger Y., La Jolla, CA, United States
Griffin, B. Albert, Del Mar, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5932474		19990803	
APPLICATION INFO.:	US 1997-955206		19971021	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ketter, James
ASSISTANT EXAMINER: Yucel, Irem
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features biarsenical molecules and target sequences that specifically react with the biarsenical molecules. Bonding partners that include target sequences, vectors that include nucleic acid sequences that encode the target sequences and host cells that include the target sequences are also featured in the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 44 USPATFULL
ACCESSION NUMBER: 1998:61456 USPATFULL
TITLE: Osteoarthritis-associated inducable isoform of nitric oxide synthetase
INVENTOR(S): Amin, Ashok R., Union, NJ, United States
Abramson, Steven B., Rye, NY, United States
PATENT ASSIGNEE(S): Hospital For Joint Diseases, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5759836		19980602	
APPLICATION INFO.:	US 1995-410739		19950327	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weber, Jon P.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2100

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An novel isoform of inducible nitric oxide synthase (OA-NOS) has been identified in osteoarthritis-affected articular cartilage. Some properties, including molecular weight, are similar to the constitutive isoform of neuronal nitric oxide synthase (ncnos) while other properties share similarity with the previously identified inducible nitric oxide (iNOS). Acetylating agents, such as aspirin and N-acetylimidazole act on both iNOS and OA-NOS by inhibiting their catalytic activities. A method is provided to screen for acetylating agents that inhibit OA-NOS, and the selective inhibition of OA-NOS by inhibitory agents is determined by comparison to a panel of different isoforms of nitric oxide synthase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 44 USPATFULL

ACCESSION NUMBER: 1998:25092 USPATFULL

TITLE: Process for the efficient production of 7-ADCA via 2-(carboxyethylthio)acetyl-7-ADCA and 3-(carboxymethylthio)propionyl-7-ADCA

INVENTOR(S): Bovenberg, Roelof Ary Lans, Rotterdam, Netherlands
Koekman, Bertus Pieter, Schipluiden, Netherlands
Hoekema, Andreas, Oegstgeest, Netherlands
Van Der Laan, Jan Metske, Breda, Netherlands
Verweij, Jan, Leiden, Netherlands
De Vroom, Erik, Leiden, Netherlands

PATENT ASSIGNEE(S): Gist-Brocades B.V., Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5726032		19980310	
	WO 9504148		19950209	
APPLICATION INFO.:	US 1996-592411		19960404	(8)
	WO 1994-EP2543		19940729	
			19960404	PCT 371 date
			19960404	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1993-202259	19930730
	EP 1993-203696	19931224

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Bierman, Muserlian and Lucas LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An overall efficient process for the preparation and recovery of 7-aminodesacetoxycephalosporanic acid (7-ADCA) via 2-(carboxyethylthio)acetyl- and 3-(carboxymethylthio)propionyl-7-ADCA, using a Penicillium chrysogenum transformant strain expressing expandase in conjunction with acyltransferase, is provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 44 USPATFULL

ACCESSION NUMBER: 1998:22199 USPATFULL

TITLE: Method of antiviral use of soluble LDL receptor

INVENTOR(S): Rubinstein, Menachem, Givat Shmuel, Israel
Novick, Daniela, Rehovot, Israel
Tal, Nathan, Rehovot, Israel

Fischer, Dina G., Rehovot, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5723438		19980303
APPLICATION INFO.:	US 1995-485131		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-92817, filed on 19 Jul 1993, now patented, Pat. No. US 5496926 which is a continuation-in-part of Ser. No. US 1993-4863, filed on 19 Jan 1993, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-100696	19920119
	IL 1992-102915	19920823

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Basham, Daryl A.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A soluble LDL receptor protein is provided. It can be isolated from cells that have been treated with an interferon, isolated from the urine of healthy human individuals or produced by recombinant techniques. The soluble LDL receptor protein is useful in protection of meals against viral infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 44 USPATFULL
ACCESSION NUMBER: 97:115118 USPATFULL
TITLE: DNA that encodes a tumor necrosis factor inhibitory protein and a recombinant method of production
INVENTOR(S): Wallach, David, Rehovot, Israel
Engelmann, Hartmut, Munich, Germany, Federal Republic of
Aderka, Dan, Holon, Israel
Rubinstein, Menachem, Givat Schmuel, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5695953		19971209
APPLICATION INFO.:	US 1992-876828		19920430 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1988-243092, filed on 12 Sep 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1987-83878	19870913

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 5 Drawing Page(s)

LINE COUNT: 1018
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified and the DNA that encodes the TNF inhibitory protein, vectors, host cells, and a recombinant method for producing the encoded protein are also set forth. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 44 USPATFULL
ACCESSION NUMBER: 97:56515 USPATFULL
TITLE: Soluble interferon .alpha.-receptor, its preparation and use
INVENTOR(S): Revel, Michel, Rehovot, Israel
Abramovich, Carolina, Yavne, Israel
Ratovitski, Edward, Gan Yavne, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co, Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5643749		19970701
APPLICATION INFO.:	US 1994-328256		19941024 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1993-107378	19931024

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Brown, Karen E.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1084
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New forms of interferon .alpha.-receptors are provided. They may be prepared recombinantly and may be used in diagnosis and therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 44 USPATFULL
ACCESSION NUMBER: 96:109073 USPATFULL
TITLE: Soluble interferon-gamma receptor fragment
INVENTOR(S): Novick, Daniela, Rehovot, Israel
Rubinstein, Menachem, Givat Shmuel, Israel
PATENT ASSIGNEE(S): Yeda Research and Development, Co., Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578707		19961126
APPLICATION INFO.:	US 1993-16992		19930212 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-578826, filed on 7 Sep 1990, now patented, Pat. No. US 5221789		

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1989-91562	19890907

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fitzgerald, David L.
LEGAL REPRESENTATIVE: Cooper, Iver P.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soluble human IFN-gamma receptor extracellular fragment and salts, functional derivatives, precursors and active fractions thereof are provided in substantially purified form. They are useful as pharmaceutically active substances for protecting against the deleterious effects of IFN-gamma, e.g. in autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 44 USPATFULL
ACCESSION NUMBER: 96:45941 USPATFULL
TITLE: DNA molecule encoding prokaryotic prolylendopeptidase
INVENTOR(S): Inaoka, Tetsuya, Takatsuki, Japan
Kokubo, Toshio, Takarazuka, Japan
Tsuru, Daisuke, Nagasaki, Japan
Yoshimoto, Tadashi, Nagasaki, Japan
PATENT ASSIGNEE(S): Ciba-Geigy (Japan) Limited, Hyogo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5521081		19960528
APPLICATION INFO.:	US 1994-227689		19940414 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-917344, filed on 23 Jul 1992, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1991-810595	19910724
	GB 1992-5457	19920312

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Grimes, Eric
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns DNA encoding prolylendopeptidase, hybrid vectors containing such DNA, transformed hosts capable of expressing prolylendopeptidase, a process for the production of prolylendopeptidase including the steps of: culturing a host organism transformed with an expression vector including a DNA coding for prolylendopeptidase and optionally, recovering the produced prolylendopeptidase; and a process for the production of a C-terminal amidated peptide from two precursors, including the steps of: placing the two precursors in contact with a prolylendopeptidase in a medium to convert the precursor peptides to the C-terminal amidated peptide, and recovering the resulting C-terminal amidated peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 44 USPATFULL
ACCESSION NUMBER: 96:19199 USPATFULL

TITLE: Process of preparing a soluble LDL receptor
INVENTOR(S): Rubinstein, Menachem, Givat Shmuel, Israel
Novick, Daniela, Rehovot, Israel
Tal, Nathan, Rehovot, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5496926		19960305
APPLICATION INFO.:	US 1993-92817		19930719 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-4863, filed on 19 Jan 1993, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-100696	19920119
	IL 1992-102915	19920823

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Teng, Sally P.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A soluble LDL receptor protein is provided. It can be isolated from cells that have been treated with an interferon, isolated from the urine of healthy human individuals or produced by recombinant techniques. The soluble LDL receptor protein is useful in protection of mammals against viral infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 44 USPATFULL
ACCESSION NUMBER: 95:58032 USPATFULL
TITLE: Inhibitor of tissue factor activity
INVENTOR(S): Buonassisi, Vincenzo, Lake Placid, NY, United States
Colburn, Patricia C., Lake Placid, NY, United States
PATENT ASSIGNEE(S): W. Alton Jones Cell Science Center, Inc., Lake Placid, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5427926		19950627
APPLICATION INFO.:	US 1994-291646		19940816 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-8586, filed on 25 Jan 1993, now patented, Pat. No. US 5356783 which is a division of Ser. No. US 1992-830462, filed on 5 Feb 1992, now patented, Pat. No. US 5219994 which is a continuation of Ser. No. US 1991-707314, filed on 29 May 1991, now abandoned which is a continuation of Ser. No. US 1988-268893, filed on 8 Nov 1988, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Prouty, Rebecca
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 798

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 44 USPATFULL

ACCESSION NUMBER: 94:90941 USPATFULL
TITLE: Inhibitor of tissue factor activity
INVENTOR(S): Buonassisi, Vincenzo, Lake Placid, NY, United States
Colburn, Patricia C., Lake Placid, NY, United States
PATENT ASSIGNEE(S): W. Alton Jones Cell Science Center, Inc., Lake Placid, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5356783		19941018
APPLICATION INFO.:	US 1993-8586		19930125 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-830462, filed on 5 Feb 1992, now patented, Pat. No. US 5219994 which is a continuation of Ser. No. US 1991-707314, filed on 29 May 1991, now abandoned which is a continuation of Ser. No. US 1988-268893, filed on 8 Nov 1988, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kepplinger, Esther M.
ASSISTANT EXAMINER: Grun, James L.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 44 USPATFULL

ACCESSION NUMBER: 93:50658 USPATFULL
TITLE: Interferon-gamma receptor fragment and its production
INVENTOR(S): Novick, Daniela, Rehovot, Israel
Rubinstein, Menachem, Givat Shmuel, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5221789		19930622
APPLICATION INFO.:	US 1990-578826		19900907 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1989-91562	19890907

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Cooper, Iver P.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 555
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soluble human IFN-gamma receptor extracellular fragment and salts, functional derivatives, precursors and active fractions thereof are provided in substantially purified form. They are useful as pharmaceutically active substances for protecting against the deleterious effects of IFN-gamma, e.g. in autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 44 USPATFULL
ACCESSION NUMBER: 93:48653 USPATFULL
TITLE: Inhibitor of tissue factor activity
INVENTOR(S): Buonassisi, Vincenzo, Lake Placid, NY, United States
Colburn, Patricia C., Lake Placid, NY, United States
PATENT ASSIGNEE(S): W. Alton Jones Cell Science Center, Inc., Lake Placid, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5219994		19930615
APPLICATION INFO.:	US 1992-830462		19920205 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-707314, filed on 29 May 1991, now abandoned which is a continuation of Ser. No. US 1988-268893, filed on 8 Nov 1988, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Guest, Shelly J.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:117729 CAPLUS
DOCUMENT NUMBER: 118:117729
TITLE: Analysis of Pseudomonas gene products using lacIq/Ptrp-lac plasmids and transposons that confer conditional phenotypes
AUTHOR(S): De Lorenzo, Victor; Eltis, Lindsay; Kessler, Birgit; Timmis, Kenneth N.
CORPORATE SOURCE: Cent. Invest. Biol., CSIC, Madrid, 28006, Spain
SOURCE: Gene (1993), 123(1), 17-24
CODEN: GENED6; ISSN: 0378-1119
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel transposon and plasmid-based broad-host-range expression systems have been developed to facilitate the genetic anal. of gene products of Pseudomonas and related gram- bacteria. The properties of lacIq/Ptrp-lac were used to construct mini-Tn5 expression vector transposons and RSF1010-derived plasmids for controlled expression and generation of conditional phenotypes. These plasmids were used to hyper-express the XylS regulator of the meta operon of the TOL plasmid of P. putida or the bphB and bphC genes of the polychlorobiphenyl-degrading pathway of

Pseudomonas sp. LB400 in different strains of Pseudomonas instead of in Escherichia coli. Specific activity of 2,3 dihydroxybiphenyl dioxygenase (bphC gene product) was increased 10-fold when hyperproduced in its native host as compared to E. coli, but under the same in vivo conditions, the XylS regulator formed protein aggregates. The other lacIq/Ptrp-lac-based expression vector presented here, transposon mini-Tn5 lacIq/Ptrc, facilitates the insertion of genetic cassettes contg. heterologous genes under the control of lac inducers in the chromosome of target bacteria, as shown by monitoring expression of a lacZ reporter cloned in mini-Tn5 lacIq/Ptrc and inserted in the chromosome of P. putida.

L4 ANSWER 34 OF 44 USPATFULL

ACCESSION NUMBER:	92:40820 USPATFULL
TITLE:	Amphiregulin: a bifunctional growth modulating glycoprotein
INVENTOR(S):	Shoyab, Mohammed, Seattle, WA, United States McDonald, Vicki L., Kent, WA, United States Bradley, James G., Woodinville, WA, United States Plowman, Gregory D., Seattle, WA, United States
PATENT ASSIGNEE(S):	Oncogen, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5115096		19920519
APPLICATION INFO.:	US 1989-297816		19890117 (7)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-181884, filed on 15 Apr 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-148327, filed on 25 Jan 1988, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Robinson, Douglas W.
ASSISTANT EXAMINER:	Weber, Jon
LEGAL REPRESENTATIVE:	Pennie & Edmonds
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT:	2689

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel cell growth regulatory factor, named Amphiregulin, is described. This extremely hydrophilic glycoprotein, having a median molecular weight of 22,500 daltons, demonstrates unusual biological activity. Amphiregulin is a bifunctional cell growth regulatory factor which exhibits potent inhibitory activity on DNA synthesis in neoplastic cells, yet promotes the growth of certain normal cells. The invention is based, in part, on the discovery that MCF-7 cells, when treated with the tumor promoting agent, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), express and secrete two distinct yet functionally equivalent forms of Amphiregulin. These two forms are structurally identical and perfectly homologous except that the truncated form lacks an amino-terminal hexapeptide found in the larger form. The Amphiregulin gene has been cloned and used to construct plasmids which direct the expression of bioactive Amphiregulin in transformed Escherichia coli cells. A wide variety of uses for Amphiregulin are encompassed by the present invention, including the treatment of wounds and cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 44 MEDLINE DUPLICATE 2

ACCESSION NUMBER:	92112859 MEDLINE
DOCUMENT NUMBER:	92112859 PubMed ID: 1730696
TITLE:	Expression of the catalytic subunit of phosphorylase phosphatase (protein phosphatase-1) in Escherichia coli.
AUTHOR:	Zhang A J; Bai G; Deans-Zirattu S; Browner M F; Lee E Y

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Florida 33101.
CONTRACT NUMBER: DK18512 (NIDDK)
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1992 Jan 25) 267 (3) 1484-90.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199202
ENTRY DATE: Entered STN: 19920308
Last Updated on STN: 19970203
Entered Medline: 19920218

AB The catalytic subunit of rabbit skeletal muscle protein phosphatase-1 was expressed in Escherichia coli. Expression of phosphatase-1 in the pET3a vector, which is based on the use of the T7 promoter, resulted in the expression of the enzyme as an insoluble aggregate. The insoluble enzyme could be renatured by high dilutions of the urea-solubilized protein in buffers containing dithiothreitol, Mn2+, and high NaCl concentrations. However, under all conditions tested, only partial (less than 5%) renaturation was achieved. A second attempt was made using a vector with the **trp-lac hybrid promoter**. In this case it was possible to express the enzyme as a soluble protein at levels of 3-4% of the soluble E. coli protein. The recombinant enzyme was purified by DEAE-Sepharose and heparin-Sepharose chromatography. Approximately 20 mg of purified enzyme was reproducibly obtained from the cells derived from 2 liters of culture. The purified enzyme had a specific activity toward phosphorylase alpha comparable to that reported for the authentic protein and had an Mr of 37,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The recombinant enzyme displayed similar sensitivities to inhibition by inhibitor-2, okadaic acid, and microcystin-LR as for the protein isolated from rabbit muscle. At all stages of purification the recombinant phosphatase behaved as an essentially inactive enzyme that required the presence of microM Mn2+ for full expression of its activity.

L4 ANSWER 36 OF 44 LIFESCI COPYRIGHT 2003 CSA
ACCESSION NUMBER: 92:6238 LIFESCI
TITLE: Expression of the catalytic subunit of phosphorylase phosphatase (protein phosphatase-1) in Escherichia coli .
AUTHOR: Zhang, Zhongjian; Bai, Ge; Deans-Zirattu, S.; Browner, M.F.; Lee, E.Y.C.
CORPORATE SOURCE: Dep. Biochem. and Mol. Biol. (R-629), Univ. Miami Sch. Med., P.O. Box 016129, Miami, FL 33101, USA
SOURCE: J. BIOL. CHEM., (1992) vol. 267, no. 3, pp. 1484-1490.
DOCUMENT TYPE: Journal
FILE SEGMENT: L
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The catalytic subunit of rabbit skeletal muscle protein phosphatase-1 was expressed in Escherichia coli . Expression of phosphatase-1 in the pET3a vector, which is based on the use of the T7 promoter, resulted in the expression of the enzyme as an insoluble aggregate. The insoluble enzyme could be renatured by high dilutions of the urea-solubilized protein in buffers containing dithiothreitol, Mn super(2+), and high NaCl concentrations. However, under all conditions tested, only partial (< 5%) renaturation was achieved. A second attempt was made using a vector with the **trp-lac hybrid promoter**. In this case it was possible to express the enzyme as a soluble protein at levels of 3-4% of the soluble E. coli protein. The recombinant enzyme was purified by DEAE-Sepharose and heparin-Sepharose chromatography. Approximately 20 mg of purified enzyme was reproducibly obtained from the cells derived from 2 liters of culture.

L4 ANSWER 37 OF 44 MEDLINE DUPLICATE 3
ACCESSION NUMBER: 92014875 MEDLINE
DOCUMENT NUMBER: 92014875 PubMed ID: 1920142
TITLE: Efficient expression of the Paramecium calmodulin gene in Escherichia coli after four TAA-to-CAA changes through a series of polymerase chain reactions.
AUTHOR: Kink J A; Maley M E; Ling K Y; Kanabrocki J A; Kung C
CORPORATE SOURCE: Department of Genetics, University of Wisconsin, Madison 53706.
CONTRACT NUMBER: GM22714 (NIGMS)
GM36386 (NIGMS)
SOURCE: JOURNAL OF PROTOZOOLOGY, (1991 Sep-Oct) 38 (5) 441-7.
Journal code: 2985197R. ISSN: 0022-3921.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199110
ENTRY DATE: Entered STN: 19920124
Last Updated on STN: 19920124
Entered Medline: 19911030

AB We have expressed the Paramecium calmodulin gene in Escherichia coli by changing the four TAA codons in this gene to CAAs. This was carried out by three polymerase chain reactions (PCRs) and then cloning the product into the expression vector pKK223-3 immediately downstream of its **trp -lac hybrid promoter**. JM109 strain of E. coli, transformed with the recombinant plasmid harboring the altered Paramecium calmodulin gene, produces a protein judged to be calmodulin. It is recognized by a monoclonal antibody to Paramecium calmodulin; it migrates with the native protein at nearly the same rate in electrophoreses; and it shows a Ca(2+)-dependent shift in electrophoretic pattern. The production of calmodulin is about 170 times as efficient with E. coli as with Paramecium in terms of unit volume of packed cells, and is about 400 times as efficient in unit volume of liquid culture. This method appears useful in site-directed mutageneses and in the heterologous productions of other ciliate proteins. A critique of this method is provided. A calmodulin half-molecule, a by-product of this project, is described.

L4 ANSWER 38 OF 44 MEDLINE DUPLICATE 4
ACCESSION NUMBER: 90251245 MEDLINE
DOCUMENT NUMBER: 90251245 PubMed ID: 2187152
TITLE: Regulation of the phosphate regulon of Escherichia coli: properties of phoR deletion mutants and subcellular localization of PhoR protein.
AUTHOR: Yamada M; Makino K; Shinagawa H; Nakata A
CORPORATE SOURCE: Department of Experimental Chemotherapy, Osaka University, Japan.
SOURCE: MOLECULAR AND GENERAL GENETICS, (1990 Feb) 220 (3) 366-72.
Journal code: 0125036. ISSN: 0026-8925.
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199006
ENTRY DATE: Entered STN: 19900720
Last Updated on STN: 19900720
Entered Medline: 19900619

AB The phoR gene is a bifunctional regulatory gene for the phosphate regulon of Escherichia coli. It acts as a negative regulator in the presence of excess phosphate and as a positive regulator with limited phosphate, through modification of PhoB protein. We constructed several phoR genes, with various deletions in the 5' regions, which were regulated by the

trp-lac hybrid promoter. The PhoR1084 and PhoR1159 proteins that lack the 83 and 158 N-terminal amino acids, respectively, retained the positive function for the expression of phoA that codes for alkaline phosphatase, but lacked the negative function. The PhoR1263 protein that lacks the 262 N-terminal amino acids was deficient in both functions. An antiserum against PhoR1084 protein was prepared. Western blot analysis of the subcellular fractions obtained by differential centrifugation indicated that the intact PhoR and PhoR1084 proteins are located in the inner membrane and cytoplasmic fractions, respectively. The results suggest that PhoR protein is anchored to the cytoplasmic membrane by the amino-terminal region.

L4 ANSWER 39 OF 44 MEDLINE DUPLICATE 5
ACCESSION NUMBER: 91013119 MEDLINE
DOCUMENT NUMBER: 91013119 PubMed ID: 2214257
TITLE: Synthesis of hepatitis B virus core antigen polypeptide in E. coli using pKK223-3 plasmid, a vector for expression, with tac promoter.
AUTHOR: Shirai M; Watanabe S; Nishioka M
CORPORATE SOURCE: Third Department of Internal Medicine, Kagawa Medical School, Japan.
SOURCE: JAPANESE JOURNAL OF EXPERIMENTAL MEDICINE, (1990 Jun) 60 (3) 97-103.
Journal code: 9800765. ISSN: 0021-5031.
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199011
ENTRY DATE: Entered STN: 19910117
Last Updated on STN: 19910117
Entered Medline: 19901114

AB A hybrid plasmid was constructed by insertion of the HBc gene encoding HBcAg into the pKK223-3 plasmid at the SmaI cleavage site in the correct direction just downstream from the tac promoter and upstream from the rrnB terminator. The recombinant plasmid carrying the HBc gene was introduced into E. coli and cloned. HBcAg was synthesized in E. coli by using the expression plasmid under the regulation of the tac promoter and rrnB terminator. The tac promoter, derived from sequences of trp and lac UV5 promoters, has identical sequences in two domains (-35 and -10 regions) with optimal distance, and the Shine-Dalgarno sequence, which enables protein synthesis to start at the ATG of the adjacent HBc gene. The nucleotide sequence of the HBc gene and its predicted amino acid sequence were almost identical to those previously reported. Purified HBcAg has a molecular weight of 21,500. This polypeptide gave a positive reaction with anti-HBcAg and anti-HBe antibodies, and was assembled into spherical particles 37 nm in diameter. The recombinant plasmid, carrying the HBc gene between the tac promoter (**trp-lac hybrid promoter**) and the rrnB terminator in expression plasmid pKK223-3, was useful for efficient expression of the HBc gene and production of HBcAg particles in E. coli.

L4 ANSWER 40 OF 44 USPATFULL
ACCESSION NUMBER: 89:4511 USPATFULL
TITLE: Vector for high level gene expression
INVENTOR(S): Anderson, David M., Rockville, MD, United States
McGuire, Jeffrey C., Frederick, MD, United States
PATENT ASSIGNEE(S): Genex Corporation, Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4798791		19890117	
APPLICATION INFO.:	US 1984-671967		19841116	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
ASSISTANT EXAMINER: Seidman, S.
LEGAL REPRESENTATIVE: Saidman, Sterne, Kessler & Goldstein
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and vectors for high level expression of genes in bacteria are disclosed. A terminal mRNA sequence from a gene coding for a stable bacterial protein mRNA is ligated to a gene coding for the desired protein adjacent the translation termination codon of the gene. The gene for the desired protein and the terminal mRNA sequence are situated in an expression vector in which the gene is operably linked to a transcription promoter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 44 MEDLINE DUPLICATE 6
ACCESSION NUMBER: 89309912 MEDLINE
DOCUMENT NUMBER: 89309912 PubMed ID: 2664013
TITLE: Production of two human 2',5'-oligoadenylate synthetase enzymes in Escherichia coli.
AUTHOR: Mory Y; Vaks B; Chebath J
CORPORATE SOURCE: Department of Virology, Weizmann Institute of Science, Rehovot, Israel.
SOURCE: JOURNAL OF INTERFERON RESEARCH, (1989 Jun) 9 (3) 295-304. Journal code: 8100396. ISSN: 0197-8357.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198908
ENTRY DATE: Entered STN: 19900309
Last Updated on STN: 19900309
Entered Medline: 19890816

AB We have isolated and characterized two types of cDNA clones corresponding to interferon (IFN)-induced 1.6- and 1.8-kb mRNAs, as encoding two different forms of the 2',5'-oligoadenylate (2'-5')A synthetase enzyme. Direct expression of the two cDNAs was obtained in Escherichia coli under the control of a **trp-lac hybrid promoter** strongly inducible in E. coli by IPTG. Bacterial extracts were tested for 2'-5'A synthetase activity after adsorption to immobilized poly(I).poly(C) or in solution. With either one of the cDNA constructions, IPTG induced 2'-5'A synthetase activity in the bacteria to levels 10 times higher per microgram of protein than those in SV80 cells treated by 500 U/ml of IFN-beta1 for 24 h. Both bacterially produced enzymes bind to double-stranded (ds)RNA and are maximally active at 100 micrograms/ml of poly(I).poly(C). Both enzymes synthesized similar 2'-5'(Ap)nA oligomers of 2 to 8 residues in length. Antibodies against a synthetic peptide common to the two enzymes were used to characterize the bacterial products on immunoblots and confirmed that the 1.6-kb RNA produces a 39-kD protein, whereas the 1.8-kb RNA encodes a 45- to 46-kD protein. The E. coli enzyme coded by the 1.6-kb mRNA was purified to nearly homogeneity. When immobilized on poly(I).poly(C) agarose, the enzyme produces, per milliliter of poly(I).poly(C), 10(3) times more 2'-5'(Ap)nA oligomer than the most active cellular extracts. Moreover, the immobilized enzyme remains stable for several months at 4 degrees C.

L4 ANSWER 42 OF 44 MEDLINE DUPLICATE 7
ACCESSION NUMBER: 85190554 MEDLINE
DOCUMENT NUMBER: 85190554 PubMed ID: 2581253

TITLE: The 140-kDa adenovirus DNA polymerase is recognized by antibodies to Escherichia coli-synthesized determinants predicted from an open reading frame on the adenovirus genome.
AUTHOR: Friefeld B R; Korn R; de Jong P J; Sninsky J J; Horwitz M S
CONTRACT NUMBER: AI08295 (NIAID)
CA11512 (NCI)
P30-CA13330 (NCI)
+
SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1985 May) 82 (9) 2652-6.
Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198506
ENTRY DATE: Entered STN: 19900320
Last Updated on STN: 19980206
Entered Medline: 19850620

AB Sequence studies of the adenovirus 2 genome have revealed the presence of a large open reading frame (ORF) from 22.9 to 14.2 map units that is believed to encode most of the adenovirus DNA polymerase (Ad Pol). An 838-base-pair fragment (19.6-17.3 map units) containing approximately 25% of this ORF has been cloned and expressed in a beta-galactosidase-chloramphenicol acetyltransferase (lacZ-CAT) expression vector under the control of the **trp-lac hybrid promoter**. This recombinant vector directed the synthesis of a 58-kDa lacZ-Ad Pol-CAT fusion protein that has CAT activity. This fusion protein was easily purified by affinity chromatography in which chloramphenicol, the substrate for CAT, was covalently bound to a matrix. Antisera were prepared against the purified 58-kDa lacZ-Ad Pol-CAT fusion protein and were found to react specifically with the 140-kDa Ad Pol by ELISA and immunoblot analysis. In addition, these antisera recognized 120- and 29-kDa polypeptides in immunoblot analysis of partially purified terminal protein precursor (pTP)-Ad Pol complex. The exact nature of the 120- and 29-kDa polypeptides is not known, but they may be breakdown products of Ad Pol. Although the lacZ-Ad Pol-CAT fusion protein is not active in any of the Ad Pol enzymatic reactions, antibody against the prokaryotic fusion protein should be useful for screening bacteria harboring plasmids that have been constructed to express the entire Ad Pol ORF.

L4 ANSWER 43 OF 44 MEDLINE DUPLICATE 8
ACCESSION NUMBER: 85157439 MEDLINE
DOCUMENT NUMBER: 85157439 PubMed ID: 2984181
TITLE: Construction and application of a promoter-probe plasmid that allows chromogenic identification in Streptomyces lividans.
AUTHOR: Horinouchi S; Beppu T
SOURCE: JOURNAL OF BACTERIOLOGY, (1985 Apr) 162 (1) 406-12.
Journal code: 2985120R. ISSN: 0021-9193.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198505
ENTRY DATE: Entered STN: 19900320
Last Updated on STN: 19990129
Entered Medline: 19850509

AB We cloned a Streptomyces coelicolor A3(2) DNA fragment which directed synthesis of a brown pigment, presumably a shunt product in the actinorhodin biosynthetic pathway, on the plasmid vector pIJ41 in Streptomyces lividans. The pigment production was observed only when the

DNA fragment was inserted downstream from a functional promoter sequence. By subcloning the fragment together with in vitro manipulation, a promoter-probe plasmid vector (pARC1) with a unique BamHI cloning site was constructed that allows chromogenic identification of transcriptional control signals in Streptomyces lividans based on the expression of the cloned pigment gene(s). The Escherichia coli tac (**trp-lac hybrid**) **promoter**, consisting of 92 base pairs and a promoter region including the leader sequence of erythromycin resistance gene (ermC) on staphylococcal plasmid pE194, when ligated in the correct orientation in the BamHI site of pARC1, promoted expression of the cloned pigment gene(s) in Streptomyces lividans, whereas the Saccharomyces cerevisiae GAL7 promoter did not. In the case of the ermC, induction of the pigment production by the addition of either erythromycin or lincomycin, but not virginiamycin, was observed. The system was also shown to be useful and convenient in isolating transcriptional control signals of Streptomyces chromosomal DNA and estimating their activities.

L4 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:419503 CAPLUS
DOCUMENT NUMBER: 105:19503
TITLE: Development of strong and stable promoter vectors with high-efficiency and tight-regulatability for protein-overproduction. 1. Modification of tac promoter vector to improve the regulatability
AUTHOR(S): Park, Sang Chul
CORPORATE SOURCE: Coll. Med., Seoul Natl. Univ., Seoul, 110, S. Korea
SOURCE: Korean Journal of Biochemistry (1985), 17(2), 123-8
CODEN: KJBID3; ISSN: 0378-8512
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The efficiency of a strong **trp-lac hybrid promoter** (tac) vector was modified for protein overprodn. by inserting lacI segments upstream of the tac promoter. To monitor the transcriptional efficiency of the plasmid, the promoterless galK gene was inserted downstream of the promoter sequences. Gene galK expression was detd. by the galactokinase activity. Insertion of lacI in the tac promoter vector decreased the basal expression of galK in the repressed state not only in an Escherichia coli galK- host strain but also in lacIq. The lacI insertion thus improved the repression capacity in the repressed state, whereas after derepression, the full expression was the same as with the tac promoter itself.